A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

This study has been terminated.

(Company decided not to pursue the development of this drug in this patient population at this time)

Sponsor:

Information provided by (Responsible Party):

Astellas Pharma Inc

ClinicalTrials.gov Identifier:

NCT01101906

First received: April 8, 2010

Last updated: December 10, 2012

Last verified: December 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	December 2011
Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)
Certification or Request for Extension to Delay Results Received:	December 10, 2012